NIH慢性骨盆疼痛综合征分型法的临床价值探讨

Clinical value of NIH consensus classification of chronic pelvic pain syndrome

目的探讨美国国立卫生研究院(NIH)的慢性骨盆疼痛综合征(CPPS)分型法的临床价值。方法选择167名CPPS患者,首诊时采用慢性前列腺炎症状评分(CPSI)问卷调查,同时行前列腺液pH值测定。予以口服氟喹诺酮治疗4周后随访,再次行CPSI问卷调查。结果比较首诊时CPSI评分、前列腺液pH值以及各部位疼痛不适发生率,IIIa型与IIIb型的差异无统计学意义(P>0.05)。治疗后IIIa型与IIIb型CPSI下降幅度的差异无统计学意义(P>0.05)。结论尚不能认为CPPS中IIIa型与IIIb型的病情及对治疗的反应存在差异,NIH的CPPS分型法的临床价值尚不能得到证实。

[Objectives] To study the clinical value of NIH consensus classification of Chronic Pelvic Pain Syndrome （CPPS）. [Methods] From September to December in 2004, 167 patients were selected for analysis, who were diagnosed as CPPS at a visit to our urology clinic. Chronic Prostatitis Symptom Index （CPSI） was used to measure symptoms. At the same time, pH value of prostatic fluid was detected. All patients were treated with fluoroquinolones for 4 weeks, and their symptoms were measured again with CPSI at 4 weeks. [Results] There was no significant difference in all inital CPSI scores, incidence rates of all types of pain or discomfort and pH value of prostatic fluid between IIIa patients and IIIB patients （P 〉0.05）. There was no significant difference in all the changes in CPSI after therapy between IIIa patients and IIIB patients too （P 〉0.05）. [Conclusions] There was no evidence that IIIa patients differ from IIIb patients in clinical situation or response to antibiotic therapy. The clinical value of NIH consensus classification of CPPS has still not been affirmed.